Invent Medic signs agreement with consultancy to facilitate start-up of US subsidiary for market and sales-related activities
Invent Medic announces that the company has signed an agreement with MLVB Inc, a consultancy focused on assisting Swedish medical technology companies during expansion to the US market. This cooperation is expected to facilitate Invent Medic’s ongoing process to establish its business in the US, including the start-up of a subsidiary for regional market and sales-related activities.
The start-up of a subsidiary constitutes an important part of Invent Medic’s expansion to the United States as this is required to handle the company’s market and sales activities in the region in an optimal way. It will also facilitate the presentation of company activities and results to shareholders and other stakeholders.
“It is exciting to have a collaboration partner in place for the start-up of our subsidiary in the United States. I look forward to collaborating with Marcie Coyne, who is in charge of MLVB Inc, within this and related areas,” says Invent Medic’s CEO Karin Bryder.
Invent Medic recently applied for market registration in the United States of its product Efemia bladder support. More than 20 million women in the United States are estimated to use some form of protection against stress incontinence and thus constitute potential users of Efemia bladder support.
For more information please contact
Karin Bryder, CEO
Phone: +46 (0)723811710
E-mail: [email protected]
About Invent Medic
Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women’s health and quality of life. The company’s products are to be safe, effective and easy to use. Invent Medic’s first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic’s share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share’s ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.
BioStock: Invent Medics vd om vägen till positivt kassaflöde
Invent Medic har fått en bra start på 2023, med ökad försäljning och minskade kostnader. Nu genomför bolaget en företrädesemission om cirka 5 Mkr i syfte att bygga vidare på de framgångar man haft med sin nya strategi. BioStock kontaktade vd Anna...
Monivent Neo100 visas med GE Healthcare Panda Warmer ResusView under jENS-kongressen
Monivent® Neo100 kommer att visas monterad på Panda™ Warmer ResusView™ i GE Healthcares monter under jENS (joint European Neonatal Societies) kongressen i Rom, 19-23 september. Panda Warmer ResusView är ett mobilt barnbord utrustat med värmekälla och en integrerad återupplivningmodul med t-stycksven...
Kommuniké från extra bolagsstämma i Invent Medic Sweden AB (publ)
Bolagsstämman bemyndigade styrelsen att, vid ett eller flera tillfällen, under tiden fram till nästa årsstämma fatta beslut om nyemission av högst 575 000 aktier mot kontant betalning och/eller med bestämmelse om apport eller kvittning eller eljest med villkor och...
New Study Highlights the Clinical Significance of TK1 SA for Early Detection of Ovarian Cancer
We are excited to announce that our recent study on different clinical applications of the TK 210 ELISA in ovarian cancer has been accepted for publication in the Karger Oncology journal. The study focused on demonstrating the clinical utility of TK1-specific activity (TK1 SA) in the early detection...